Should doctors prescribe Leqembi (lecanemab) to women with early Alzheimer’s Disease? The evidence-based answer is probably No

By SharpBrains | June 28, 2023

Wel­come to a new edi­tion of Sharp­Brains e‑newsletter, fea­tur­ing this time a range of inter­ven­tions for brain/ cognitive/ men­tal health plus a few brain teasers to test our per­cep­tion and cog­ni­tive skills. #1. Should doc­tors pre­scribe lecanemab (Leqem­bi) to women? The answer, giv­en avail­able evi­dence, is prob­a­bly No Huge (and most­ly over­looked) red flag regard­ing newly…

Read More

Should doctors prescribe lecanemab (Leqembi) to women? The answer, given available evidence, is probably No

By Prof. Michael Valenzuela | May 10, 2023

Data from the CLARITY tri­al ear­li­er this year was sup­posed to be the crown­ing glo­ry of the amy­loid hypoth­e­sis, vin­di­ca­tion for pro­po­nents of this long-held but much-maligned the­o­ry of Alzheimer’s dis­ease. Yet the results left many feel­ing under­whelmed, and even the study authors non­com­mit­tal. The CLARITY tri­al has many admirable fea­tures. It recruit­ed close to…

Read More

On the 7 Habits of Highly Stress-Resilient Minds, cognitive screenings, anti-amyloid drugs, and more

By SharpBrains | April 27, 2023

Wel­come to a new edi­tion of Sharp­Brains e‑newsletter, this time cov­er­ing the lat­est devel­op­ments in stress research, med­i­ta­tion, vir­tu­al real­i­ty, anti-amy­loid drugs, cog­ni­tive screen­ings, and more. #1. The 7 Habits of High­ly Stress-Resilient Minds “Any­thing worth doing will have aspects of stress woven through: chal­lenge, dis­com­fort, risk. We can’t change that. But what we can change is…

Read More

CMS: anti-amyloid drug Leqembi (lecanemab) doesn’t meet the “reasonable and necessary” standard required for wider Medicare coverage

By SharpBrains | February 28, 2023

CMS Sticks to Sharply Lim­it­ed Cov­er­age of New Alzheimer’s Drug, Leqem­bi (Man­aged Health­care Exec­u­tive): For now, CMS (Note: Cen­ters for Medicare & Med­ic­aid Ser­vices) is stick­ing to the cov­er­age deci­sion it made for Aduhelm (adu­canum­ab) and apply­ing it Leqem­bi (lecanemab). The deci­sion lim­its Medicare cov­er­age of the two Alzheimer disease’s drugs to Medicare ben­e­fi­cia­ries who…

Read More